Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 7/20 | 0.61 |
| ▸ | CA2 | P00918 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.54 |
| ▸ | CA4 | P22748 | 3/20 | 0.54 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326533 | 0.93 | HSD17B10 (0.64) | HSD17B10CA1CA2ALDH1A1SIGMAR1 | |
| SCHEMBL3324949 | 0.85 | SIGMAR1 (0.74) | HSD17B10CA1CA2ALDH1A1SIGMAR1 | |
| SCHEMBL3327021 | 0.84 | SIGMAR1 (0.64) | HSD17B10CA1CA2ALDH1A1SIGMAR1 | |
| SCHEMBL3387320 | 0.82 | SIGMAR1 (0.61) | HSD17B10CA1CA2ALDH1A1SIGMAR1 | |
| SCHEMBL3712996 | 0.79 | SIGMAR1 (0.73) | ALDH1A1SIGMAR1MAPK1GFER | |
| SCHEMBL3326549 | 0.78 | SIGMAR1 (0.59) | HSD17B10CA1CA2ALDH1A1SIGMAR1 | |
| SCHEMBL3326554 | 0.78 | SIGMAR1 (0.59) | HSD17B10CA1CA2ALDH1A1SIGMAR1 | |
| SCHEMBL13263773 | 0.78 | CA2 (0.65) | CA1CA2CA12CA4CA6 | |
| SCHEMBL3322300 | 0.77 | USP2 (0.70) | HSD17B10CA1CA2ALDH1A1SIGMAR1 | |
| SCHEMBL3322296 | 0.76 | USP2 (0.61) | HSD17B10CA1CA2ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2010-05-20 | — | — | US | claimed |
| EP-2142499-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | Unimed Pharma, Spol. S R.O. (SK) | 2010-01-13 | — | — | EP | claimed |
| WO-2008130332-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2008-10-30 | — | — | WO | claimed |
| US-8193184-B2 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use | Unimed Pharma, SPOL, S.R.O. (SK) | 2012-06-05 | — | — | US | disclosed |
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2010-05-20 | — | — | US | disclosed |
| EP-2142499-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | Unimed Pharma, Spol. S R.O. (SK) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008130332-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | ARSA, SMS, SULT1E1 | HSD17B10 2022/4885CA1 653/4885CA2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.